Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 9

ESCI
Impact Factor

Blood and Lymphatic Cancer: Targets and Therapy

ISSN: 1179-9889


       

Archive: Volume 9, 2019

Review

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Lai C, Kandahari AM, Ujjani C

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:63-71

Published Date: 9 December 2019

Original Research

Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1

Narimani M, Sharifi M, Jalili A

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:53-61

Published Date: 27 November 2019

Review

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

Carrà G, Cartellà A, Maffeo B, Morotti A

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:45-52

Published Date: 6 November 2019

Original Research

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens

Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43

Published Date: 19 August 2019

Review

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:19-32

Published Date: 27 June 2019

Review

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Schieber M, Ma S

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:9-17

Published Date: 12 March 2019

Review

Strategies for minimal residual disease detection: current perspectives

Andreani G, Cilloni D

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:1-8

Published Date: 12 February 2019